| pubmed-article:3929218 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0033809 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0681828 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:3929218 | lifeskim:mentions | umls-concept:C0145918 | lld:lifeskim |
| pubmed-article:3929218 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:3929218 | pubmed:dateCreated | 1985-10-17 | lld:pubmed |
| pubmed-article:3929218 | pubmed:abstractText | Activity of ticarcillin combined with clavulanic acid against 203 P. aeruginosa strains was studied. 159 strains produced a constitutive beta-lactamase with resistance to ticarcillin (MIC less than 128 mg/l) as a result. Minimal inhibitory concentrations (MICs) were determined using the agar dilution method for ticarcillin alone and combined with 4 and 8 mg/l clavulanic acid. Addition of clavulanic acid failed to change the activity of ticarcillin on ticarcillin-susceptible stains and on strains producing a constitutive cephalosporinase. A synergic effect was demonstrated for PSE and TEM type beta-lactamase producers and for OXA type beta-lactamase producers (4 halving dilutions and 1 to 2 halving dilutions respectively). However, because of the levels of baseline MICs, the combination brought the MIC of ticarcillin below the cutoff level for a small percentage of PSE strains (6%), moderate percentage of OXA strains (17 to 50%) and significant percentage of TEM strains. These percentages were slightly higher with 8 mg than 4 mg clavulanic acid. Given current data on the prevalence of the various beta-lactamases among resistant strains now being isolated in France, the ticarcillin + clavulanic acid combination will enable to achieve an MIC less than 128 mg/l for 11% (with 4 mg) or 16% (with 8 mg) of resistant strains. | lld:pubmed |
| pubmed-article:3929218 | pubmed:language | fre | lld:pubmed |
| pubmed-article:3929218 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3929218 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3929218 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3929218 | pubmed:month | May | lld:pubmed |
| pubmed-article:3929218 | pubmed:issn | 0369-8114 | lld:pubmed |
| pubmed-article:3929218 | pubmed:author | pubmed-author:ThabautAA | lld:pubmed |
| pubmed-article:3929218 | pubmed:author | pubmed-author:MeyranMM | lld:pubmed |
| pubmed-article:3929218 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3929218 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:3929218 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3929218 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3929218 | pubmed:pagination | 408-11 | lld:pubmed |
| pubmed-article:3929218 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:meshHeading | pubmed-meshheading:3929218-... | lld:pubmed |
| pubmed-article:3929218 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3929218 | pubmed:articleTitle | [In vitro study of the effects of a ticarcillin-clavulanic acid combination on Pseudomonas aeruginosa as a function of resistant phenotypes]. | lld:pubmed |
| pubmed-article:3929218 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3929218 | pubmed:publicationType | English Abstract | lld:pubmed |
